A series of novel 6-(4-benzylpiperazin-1-yl) benzodioxanes were prepared and screened at selected dopamine receptor subtypes. 6-(4-[4-Chlorobenzyl] piperazin-1-yl) benzodioxane (2d) had high affinity and selectivity for the D4 dopamine receptor subtype and was identified as a D4 antagonist via its attenuation of dopamine-induced GTPγ35S binding at the D4 receptor.
[Song, Jiho; Kim, Young Jin; Min, Kyung Hoon; Lee, Hyun-E; Kim, Su Yeon; Kim, Dong-Seok Bioorganic and Medicinal Chemistry Letters, 2012 , vol. 22, # 22 p. 6943 - 6946,4]